Market News & Trends
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study
Cocrystal Pharma, Inc. recently announced dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered…
Pharmazz Announces FDA Clearance of an IND Application for Phase 2 Clinical Trial
Pharmazz recently announced US FDA clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of centhaquine as an adjuvant to…
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Denali Therapeutics Inc. recently announced dosing has begun in a Phase 1/2 clinical trial of DNL593 (PTV:PGRN) for the potential treatment of frontotemporal dementia (FTD)…
Vibalogics Completes Major Milestone in $50-Million Facility Expansion
Vibalogics has recently announced the completion of its expansion project at its GMP facility in Cuxhaven, Germany. The new building features biosafety level (BSL) 2…
Atossa Therapeutics Announces Issuance of Key US Patent Covering Endoxifen
Atossa Therapeutics, Inc. recently announced the US Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy…
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. The positive final analysis included…
DNAnexus Secures $200-Million Funding to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine
DNAnexus, Inc. recently announced a $200-million financing round to accelerate the global adoption of its technology, translating the world’s complex multi-omics and clinical data into…
Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufacturing With HPAPI
Enteris BioPharma, Inc. recently announced the publication of a new white paper, titled HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity. The…
Alcami Adds Additional Formulation Development Capabilities
Alcami recently announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the…
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor in Human Skin Model of Vitiligo
VYNE Therapeutics Inc. recently announced positive preclinical data in an ex vivo skin model of vitiligo. In the preclinical model, pan-bromodomain and extra-terminal (BET) inhibitor…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….